Research Article

Clinical Effect of Revascularization Strategies and Pharmacologic Treatment on Long-Term Results in Patients with Advanced Peripheral Artery Disease with TASC C and D Femoropopliteal Lesions

Table 3

Study endpoints associated with treatment methods.

ParametersEVT group (n = 94)Bypass group (n = 93) value

Successful intervention at one month93 (100)94 (100)
Direct revascularization43 (45.7)47 (50.5)0.512
Postintervention ABI
 One month0.92 ± 0.10.95 ± 0.160.113
 36 months0.53 ± 0.160.72 ± 0.14<0.001
Primary patency
 12 months70 (74.5)76 (81.7)0.231
 24 months52 (55.3)62 (66.7)0.112
 36 months37 (39.4)55 (59.1)0.007
Secondary patency
 24 months74 (78.7)79 (84.9)0.27
 36 months61 (64.9)73 (78.5)0.039
Male25 (26.6)31 (33.3)0.315
AFSR at 36 months64 (68.1)71 (76.3)0.208
LEA at 36 months32 (34.0)29 (31.2)0.954
Major8 (8.5)8 (8.6)
Minor23 (24.5)21 (22.6)
24-month mortality15 (16.0)9 (9.7)0.199
36-month mortality27 (28.7)18 (19.4)0.134
12-month CAD events15 (16.0)17 (18.3)0.673
24-month CAD events28 (29.8)26 (28.0)0.782
36-month CAD events30 (31.9)29 (31.2)0.914
24-month CVA events5 (5.3)10 (10.8)0.171
36-month CVA events10 (10.6)11 (11.8)0.797
Concomitant medications
Cilostazol treatment
 ≤3 months31 (33.0)23 (24.7)0.213
 >3 months63 (67.0)70 (75.3)
Statin treatment32 (34.0)42 (45.2)0.120
Antiplatelet therapy93 (1001)94 (100)1.000

ABI, ankle brachial index; AFSR, amputation-free survival rate; CAD, coronary artery disease; CVA, cerebrovascular accident; EVT, endovascular therapy; LEA, lower-extremity amputation; MALE, major adverse limb event.